ArticleJournal of medicinal chemistry2022
Ruthenium(II)-Tris-pyrazolylmethane Complexes Inhibit Cancer Cell Growth by Disrupting Mitochondrial Calcium Homeostasis.
Article in Journal of medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 57 citations in OpenAlex.
- Article
- FALCON-qPCR: a new method for the quantification of oxidative lesions in mitochondrial DNA.Bioanalysis · 2025Article
- MCU-i4, a mitochondrial CaOncology research · 2025Article
- A Novel Substituted Benzo[Journal of medicinal chemistry · 2024Article
- The Elusive Biological Activity of Scorpionates: A Useful Scaffold for Cancer Therapy?Molecules (Basel, Switzerland) · 2024Review
- Supramolecular delivery of dinuclear ruthenium and osmium MCU inhibitors.Inorganic chemistry frontiers · 2024Article
- Selective Targeting of Regulated Rhabdomyosarcoma Cells by Trinuclear Ruthenium(II)-Arene Complexes.Journal of medicinal chemistry · 2024Article
- Exploration of newly synthesized transition metal(II) complexes for infectious diseases.Future medicinal chemistry · 2024Article
- Complexes of Ruthenium(II) as Promising Dual-Active Agents against Cancer and Viral Infections.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Anticancer Potential of Diruthenium Complexes with Bridging Hydrocarbyl Ligands from Bioactive Alkynols.Inorganic chemistry · 2023Article
- Triarylphosphine-Coordinated Bipyridyl Ru(II) Complexes Induce Mitochondrial Dysfunction.Inorganic chemistry · 2023Article
- Investigation of Cobalt(III) Cage Complexes as Inhibitors of the Mitochondrial Calcium Uniporter.European journal of inorganic chemistry · 2023Article
- A Fluorogenic Inhibitor of the Mitochondrial Calcium Uniporter.Angewandte Chemie (International ed. in English) · 2023Article
- A ferrocene-containing analogue of the MCU inhibitor Ru265 with increased cell permeability.Inorganic chemistry frontiers · 2023Article
- Enriching Chemical Space of Bioactive Scaffolds by New Ring Systems: Benzazocines and Their Metal Complexes as Potential Anticancer Drugs.Inorganic chemistry · 2022Article
- Carboxylate-Capped Analogues of Ru265 Are MCU Inhibitor Prodrugs.Inorganic chemistry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While ruthenium arene complexes have been widely investigated for their medicinal potential, studies on homologous compounds containing a tridentate tris(1-pyrazolyl)methane ligand are almost absent in the literature. Ruthenium(II) complex
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.